Compare Stocks

Enter up to five stock symbols separated by a comma or space (ex. BAC,WFC,JPM,LON:BARC).
Date Range: 

 Enzo BiochemCelcuityBioceptAnPac Bio-Medical ScienceMiragen Therapeutics
SymbolNYSE:ENZNASDAQ:CELCNASDAQ:BIOCNASDAQ:ANPCNASDAQ:MGEN
Price Information
Current Price$3.46$21.60$4.60$5.77$15.66
52 Week RangeN/ABuyBuyN/ABuy
MarketRank™
Overall Score0.71.01.20.70.9
Analysis Score0.01.53.50.01.4
Community Score2.52.52.52.92.7
Dividend Score0.00.00.00.00.0
Ownership Score0.80.80.00.00.0
Earnings & Valuation Score0.00.00.00.60.6
Analyst Ratings
Consensus RecommendationN/ABuyBuyN/ABuy
Consensus Price TargetN/A$21.50$20.00N/A$16.33
% Upside from Price TargetN/A-0.46% downside334.78% upsideN/A4.30% upside
Trade Information
Market Cap$166.87 million$265.42 million$61.65 million$64.63 million$61.20 million
Beta0.891.350.86N/A1.66
Average Volume1,222,209267,785581,200797,373134,027
Sales & Book Value
Annual Revenue$76.02 millionN/A$5.53 million$1.56 million$4.46 million
Price / Sales2.20N/A11.1541.4313.72
CashflowN/AN/AN/AN/AN/A
Price / CashN/AN/AN/AN/AN/A
Book Value$1.22 per share$1.88 per share$2.35 per share($1.37) per share$6.78 per share
Price / Book2.84N/A1.96-4.212.31
Profitability
Net Income$-28,520,000.00$-7,360,000.00$-25,140,000.00$-14,520,000.00$-41,870,000.00
EPSN/A($0.72)($12.20)($1.62)($20.09)
Trailing P/E RatioN/AN/AN/AN/AN/A
Forward P/E Ratio∞N/A∞N/AN/A
P/E GrowthN/AN/AN/AN/AN/A
Net Margins-24.36%N/A-237.01%N/A-1,393.50%
Return on Equity (ROE)-27.05%-52.57%-114.46%N/A-141.66%
Return on Assets (ROA)-14.76%-49.69%-82.15%N/A-88.74%
Dividend
Annual PayoutN/AN/AN/AN/AN/A
Dividend YieldN/AN/AN/AN/AN/A
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/AN/AN/AN/AN/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt
Debt-to-Equity Ratio0.08%N/A0.06%N/A0.20%
Current Ratio2.09%13.54%2.85%0.94%4.23%
Quick Ratio1.85%13.54%2.52%0.93%4.23%
Ownership Information
Institutional Ownership Percentage60.38%18.56%8.18%0.02%N/A
Insider Ownership Percentage9.40%43.50%0.40%N/A1.10%
Miscellaneous
Employees408308811145
Shares Outstanding48.23 million12.29 million13.40 million11.20 million3.91 million
Next Earnings Date6/14/2021 (Estimated)5/6/2021 (Estimated)5/12/2021 (Estimated)5/17/2021 (Estimated)N/A
OptionableOptionableNot OptionableOptionableNot OptionableNot Optionable
SourceHeadline
Miragen Therapeutics (NASDAQ:MGEN) versus Exagen (NASDAQ:XGN) Head-To-Head ContrastMiragen Therapeutics (NASDAQ:MGEN) versus Exagen (NASDAQ:XGN) Head-To-Head Contrast
americanbankingnews.com - March 28 at 10:46 PM
Miragen Therapeutics, Inc. (NASDAQ:MGEN) Given Average Recommendation of "Buy" by BrokeragesMiragen Therapeutics, Inc. (NASDAQ:MGEN) Given Average Recommendation of "Buy" by Brokerages
americanbankingnews.com - March 28 at 7:20 AM
Miragen Therapeutics (NASDAQ:MGEN) Shares Cross Below 50 Day Moving Average of $18.92Miragen Therapeutics (NASDAQ:MGEN) Shares Cross Below 50 Day Moving Average of $18.92
americanbankingnews.com - March 19 at 2:42 AM
MiRagen rebrands to Veridian months after acquisition, names new CEOMiRagen rebrands to Veridian months after acquisition, names new CEO
dailycamera.com - January 19 at 11:26 PM
miRagen Therapeutics Announces Company Name Change to Viridian Therapeutics and New Executive Appointments, Including Expansion of Leadership TeammiRagen Therapeutics Announces Company Name Change to Viridian Therapeutics and New Executive Appointments, Including Expansion of Leadership Team
finance.yahoo.com - January 19 at 4:34 PM
Miragen licenses engineering platform for use in future drug candidateMiragen licenses engineering platform for use in future drug candidate
dailycamera.com - December 17 at 7:49 PM
Miragen licenses engineering platform for use in future flagship drug candidateMiragen licenses engineering platform for use in future flagship drug candidate
bizwest.com - December 17 at 2:48 PM
miRagen Enters into License Agreement with Xencor for use of Xtend™ Antibody Technology for Investigational Antibodies to Treat Thyroid Eye DiseasemiRagen Enters into License Agreement with Xencor for use of Xtend™ Antibody Technology for Investigational Antibodies to Treat Thyroid Eye Disease
finance.yahoo.com - December 17 at 9:47 AM
Boulder-based Miragen’s medical chief resignsBoulder-based Miragen’s medical chief resigns
dailycamera.com - December 8 at 5:55 PM
Miragen’s medical chief resignsMiragen’s medical chief resigns
bizwest.com - December 7 at 9:41 PM
Biotechnology StocksBiotechnology Stocks
money.usnews.com - November 25 at 7:32 PM
MiRagen reports loss, effects reverse stock splitMiRagen reports loss, effects reverse stock split
dailycamera.com - November 12 at 10:02 PM
Miragen Therapeutics EPS beats by $0.03Miragen Therapeutics EPS beats by $0.03
seekingalpha.com - November 10 at 6:18 PM
miRagen Reports Third Quarter 2020 Financial Results and Provides Corporate UpdatesmiRagen Reports Third Quarter 2020 Financial Results and Provides Corporate Updates
finance.yahoo.com - November 10 at 6:18 PM
Value-Added Acquisition Clears the Runway for Miragen TherapeuticsValue-Added Acquisition Clears the Runway for Miragen Therapeutics
feedproxy.google.com - November 9 at 12:04 PM
Iovance (IOVA) Q3 Earnings Beat Estimates, Pipeline in FocusIovance (IOVA) Q3 Earnings Beat Estimates, Pipeline in Focus
finance.yahoo.com - November 9 at 9:46 AM
Miragen Therapeutics IncMiragen Therapeutics Inc
bloomberg.com - November 1 at 12:02 AM
MiRagen Therapeutics shares skyrocket 156% on Viridian acquisition, inks PIPE deal for $91MMiRagen Therapeutics shares skyrocket 156% on Viridian acquisition, inks PIPE deal for $91M
seekingalpha.com - October 30 at 1:51 PM
Violin music: Miragen’s buy of Viridian with TED prospect mutes recent sad notesViolin music: Miragen’s buy of Viridian with TED prospect mutes recent sad notes
bioworld.com - October 29 at 8:59 AM
Lilly, Novartis continue to push ahead with COVID-19 effortsLilly, Novartis continue to push ahead with COVID-19 efforts
bioworld.com - October 29 at 8:59 AM
Looking Into Miragen Therapeutics's Return On Capital EmployedLooking Into Miragen Therapeutics's Return On Capital Employed
finance.yahoo.com - October 29 at 8:59 AM
Miragen Therapeutics News: Why MGEN Stock Is Skyrocketing TodayMiragen Therapeutics News: Why MGEN Stock Is Skyrocketing Today
feedproxy.google.com - October 28 at 1:57 PM
Investors flood Miragen after acquisition, shift to eye-disease treatmentInvestors flood Miragen after acquisition, shift to eye-disease treatment
bizwest.com - October 28 at 1:30 PM
Looking Into Miragen Therapeuticss Return On Capital EmployedLooking Into Miragen Therapeutics's Return On Capital Employed
benzinga.com - October 28 at 1:30 PM
MGEN Stock: Explanation Of The 66% Stock Price IncreaseMGEN Stock: Explanation Of The 66% Stock Price Increase
pulse2.com - October 28 at 1:30 PM
DateCompanyBrokerageAction
2/17/2021CelcuityCraig HallumBoost Price Target
2/17/2021CelcuityHC WainwrightReiterated Rating
12/11/2020BioceptMaxim GroupInitiated Coverage
5/14/2020BioceptBrookline Capital ManagementInitiated Coverage
10/3/2018BioceptDawson JamesReiterated Rating
5/23/2018BioceptWestpark CapitalDowngrade
12/31/2020Miragen TherapeuticsOppenheimerReiterated Rating
12/15/2020Miragen TherapeuticsJMP SecuritiesInitiated Coverage
11/24/2020Miragen TherapeuticsWedbushReiterated Rating
8/10/2020Miragen TherapeuticsJefferies Financial GroupReiterated Rating
12/12/2019Miragen TherapeuticsRobert W. BairdDowngrade
12/31/2018Miragen TherapeuticsB. RileyInitiated Coverage
(Data available from 4/11/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)
Comparison Ideas:

As Featured By:

MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.